The Joel E. Johnson, Sr., Research Acceleration Fund in Dystonia will support ongoing dystonia research in the Division of Movement Disorders, part of the Department of Neurology.
‚ÄúDystonia has several forms and may be hereditary or caused by factors such as physical trauma, infection or reaction to a pharmaceutical, however most cases have no known cause,‚ÄĚ said David G. Standaert, M.D., Ph.D., professor and chair of the Department of Neurology. ‚ÄúTreatment is difficult and has been limited to minimizing the symptoms. At present, there is no cure.‚ÄĚ
Joel Johnson, Sr., who passed away at age 98 in 1997, was a 1921 graduate of the University of Alabama Law School. His father, J.J. Johnson, founded Citizen‚Äôs Bank in Geneva, Ala., in 1901. J.J. Johnson, Joel Johnson and his late son Joel, Jr., operated the bank for more than 100 years until it merged with the Bank of the Ozarks in 2012.
‚ÄúThe Johnsons were very civic-minded individuals, giving of their time and resources to the community,‚ÄĚ said Nell Johnson, his daughter-in-law. ‚ÄúThis gift will perpetuate their memory as civic, business, church and philanthropic leaders.‚ÄĚ
The gift will help UAB create a world-class research program in dystonia.
‚ÄúIt‚Äôs gratifying to know that the Joel E. Johnson, Sr., Research Acceleration Fund in Dystonia will help bolster patient care, clinical research and basic laboratory research in search of new treatments ‚Äď and ultimately a cure ‚Äď for dystonia here in Alabama,‚ÄĚ said Lesley Laird, Mrs. Johnson‚Äôs daughter.
In addition to providing clinical care and research support, the grant will help UAB recruit additional faculty researchers and clinicians who will focus on dystonia, pursuing promising, novel research projects and accelerating ongoing research projects aimed at developing new treatments and cures.
The grant will also assist in recruitment of pre- and post-doctoral researchers to UAB to train as the next generation of dystonia clinicians and scientists.
‚ÄúIt can take more than a decade for a new therapy to go from the pre-clinical discovery stage to approval by the FDA for widespread use in humans,‚ÄĚ said Standaert. ‚ÄúOne of our primary goals is to have as many lines of research going as possible and accelerate the translational process, moving basic scientific discoveries from the laboratory to clinical use as rapidly and safely as possible.‚ÄĚ
|In addition to providing clinical care and research support, the grant will help UAB recruit additional faculty researchers and clinicians who will focus on dystonia, pursuing promising, novel research projects and accelerating ongoing research projects aimed at developing new treatments and cures.|
‚ÄúThe UAB Movement Disorders Program has positioned itself to take full advantage of this new knowledge and has made tremendous progress toward reaching our goal of becoming a leader nationally and internationally,‚ÄĚ Standaert said. ‚ÄúFurthermore, UAB houses the Center for Neurodegeneration and Experimental Therapeuticss, a world-class, state-of-the-art translational research center dedicated to discovering new potential treatments and cures for neurodegenerative disorders, including dystonia.‚ÄĚ
Standaert serves as a member of the Scientific Advisory Board for the Bachmann-Strauss Dystonia & Parkinson Foundation, and he has also served as an advisor for the Dystonia Medical Research Foundation (DMRF).
The DMRF suggests as many as 300,000 people in North America have dystonia.